Since the IL-23/IL-17 axis is considered crucial in the pathogenesis of psoriasis, and biologics targeting this axis are used to treat psoriasis, the results of the present study provide a bright prospective that Ac-RLYE can also be developed as a treatment for psoriasis. The gene discussed is IL17A; the disease is psoriasis.